Market Signal Briefing

A $1 billion deal could see XRPL handle trillions in Fortune 500 capital — XRP price predictions now eye new highs with mainstream demand.

CMB International has partnered with BNB Chain to bring its $3.8 billion Money Market Fund onchain, supported by DigiFT and Onchain. The move gives investors blockchain-based access to one of Asia-Pacific's top-performing institutional funds. BNB Chain Brings $3.

SummaryThis article highlights top ReFa/Ro dividend stocks for September 2025, focusing on high yield and analyst-projected returns through September 2026.MFA Financial, Hafnia, and Energy Transfer lead the list, with projected net gains ranging from 30.84% to 70.61%.All top-ten ReFa/Ro "dogs" meet the ideal criterion: dividends from $1,000 invested exceed their share price, appealing to income-focused investors.Caution is advised as some high-yield stocks show negative free-cash-flow margins; 28 of 39 ReFa/Ro stocks are deemed "safer" with dividends supported by cash-flow and 17 of those are Ideal.Prior to September 30, 2025, my REaders mentioned 39 equities in their comments about my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about their ReFa/Ro. damedeeso/iStock via Getty Images

Reader Selections Since May, 2017, any dividend-paying stock mentioned in a message, e-mail or comment to the author has been fair game for a reader favorite listing in this series of articles. Thus, It is possible that only rogues and

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: This article is for informational and educational purposes only and should not be construed to constitute investment advice. Nothing contained herein shall constitute a solicitation, recommendation or endorsement to buy or sell any security. Prices and returns on equities in this article except as noted are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling same.
Graphs and charts were compiled by Rydlun & Co., LLC from data derived from Indexarb; YCharts; finance.yahoo.com; analyst mean target price by YCharts. Open source dog art from dividenddogcatcher.com.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

LOS ANGELES--(BUSINESS WIRE)--Grindr Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – GRND.

- NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - Highlights: First-pass metallurgical testing from Eureka deposit, Nikolai nickel project, Alaska nearing completion; results anticipated in November 2025 Eureka Internal "Options Study" nearing completion; will lead to Preliminary Economic Assessment to be published in 2026 Continued pursuit of US government grant funding for Nikolai project Hydrometallurgical amenability testing to begin on Eureka concentrates Incentive stock options and restricted shares units granted VANCOUVER, BC / ACCESS Newswire / October 17, 2025 / Alaska Energy Metals Corporation (TSX-V:AEMC)(OTCQB:AKEMF) ("AEMC" or the "Company") provides the following update on its activities. Metallurgical testing has been ongoing at SGS laboratories in Lakefield, Ontario.

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE:BAX) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

If you suffered a loss on your Baxter investments, you have until December 15, 2025 to request lead plaintiff appointment. Follow the link below for more information:

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Happened?

On April 7, 2025, safety concerns regarding Baxter’s Novum IQ Large Volume Pump (“Novum LVP”), a device used for the delivery of intravenous fluids that carry medications, blood products, and nutrients to patients, began to surface after a Missouri news outlet reported serious safety issues relating to inaccurate infusion with the Novum LVPs based on information from a whistleblower. Just weeks after the whistleblower report, on April 24, 2025, Baxter sent customers a warning letter about potential underinfusion risks associated with the Novum LVP, disclosing only one serious injury linked to this issue. Then, on July 14, 2025, Baxter issued a second warning letter reiterating the underinfusion risks and adding the risk of overinfusion with the Novum LVP. The letter also revealed that Baxter had received 79 reports of serious injury and two reports of patient deaths related to the Novum LVP. Finally, on July 31, 2025, the Company announced that it had decided to “voluntarily and temporarily pause shipments and planned installations of the Novum LVP” and that the Company was “unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs.” On this news, the price of Baxter shares declined by $6.29 per share, or approximately 22.4%, from $28.05 per share on July 30, 2025, to close at $21.76 on July 31, 2025.

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of February 23, 2022 through July 30, 2025, inclusive (“the Class Period”). The lawsuit alleges that, throughout the Class Period, Defendants misled investors by failing to disclose that: (i) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (ii) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (iii) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; and (iv) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1171
https://www.kmllp.com
[email protected]

After a steep month-long slide, Broadcom NASDAQ: AVGO just turned its fortunes around in a huge way.

Broadcom Today

$349.33 -4.82 (-1.36%)

As of 04:00 PM Eastern

52-Week Range$138.10▼

$374.23Dividend Yield0.68%

P/E Ratio89.11

Price Target$372.33

Shares of the chip giant reached an all-time high closing price of nearly $369 on Sept. 9. This came as markets reacted to CEO Hock Tan’s AI-incentivized pay package. But the gains were short-lived, with the stock dropping around 12% by market close on Oct. 10. MarketBeat noted at the time that the 10% single-day gain Tan’s package resulted in felt unwarranted. Thus, it wasn’t overly surprising to see shares correct.

However, everything changed on Oct. 13, when Broadcom announced its latest AI chip customer: OpenAI. This deal sent shares up 10% in one day as markets reacted to the billions in new sales Broadcom should generate from the deal. Here’s why the OpenAI deal is a game-changer—and what it means for AVGO going forward.

Broadcom Matches NVIDIA in AI Power, Surpasses AMD
In the announcement, Broadcom said that OpenAI will deploy ten gigawatts (GW) of its custom AI accelerators, also known as XPUs. For reference, that’s equal to around one-third of the energy needed to power the state of New York during peak summer demand. That’s a lot of chips.

Broadcom’s deal is notably equal in size to the 10 GW deal OpenAI signed with NVIDIA NASDAQ: NVDA. It is also much larger than the 6 GW deployment that OpenAI has agreed to with Advanced Micro Devices NASDAQ: AMD. This clearly shows that although AMD is gaining traction, Broadcom and NVIDIA are still in a league of their own when it comes to AI chips.

Broadcom will make not only custom AI XPUs for OpenAI but networking chips as well. While XPUs perform the hard calculations that make AI workloads go, networking chips allow different XPUs to communicate. Thus, Broadcom’s deal with OpenAI includes a large bundle of products, making it much more significant than an XPU deal alone.

XPUs typically make up 70% of Broadcom's AI semiconductor revenues, while networking chips make up the other 30%. Networking’s share of this total has notably reached as high as 40% in recent quarters. Each is a very significant part of the company's AI business, underscoring how substantial the inclusion of both technologies in the deal is.

Furthermore, this provides evidence that Broadcom’s Ethernet-based networking technology is competitive with NVIDIA’s networking offerings. Staying competitive on this front is particularly important now, given that NVIDIA’s OpenAI deal also included networking equipment. The networking battle between these two companies is somewhat overlooked but highly important. With this win, Broadcom continues to show it is a first-class name in AI.

Broadcom’s Q3 Announcement Looks Even Better Now
Another interesting wrinkle in this story is that analysts were wrong about Broadcom, but in a great way.

In its Q3 earnings call, Broadcom announced that it had gained another hyperscaler customer for its AI chips. After the company disclosed that this deal was worth around $10 billion, many believed the customer was OpenAI. When asked directly about this, the President of Broadcom’s Semiconductor Solutions Group, Charlie Kawwas, refuted the claim. He said that he had not received a $10 billion purchase order from his “good friend Greg," referring to OpenAI President Greg Brockman.

Thus, Broadcom has added not only one but two major customers over the last few months: OpenAI and someone else. This makes the company’s past statement that it gained a new hyperscaler customer even more impressive than before.

AVGO Continues Its Momentum, Updated Targets See 13%+ Upside
Broadcom Stock Forecast Today12-Month Stock Price Forecast:
$372.33
6.45% Upside

Buy
Based on 34 Analyst Ratings

Current Price$349.76High Forecast$460.00Average Forecast$372.33Low Forecast$210.00Broadcom Stock Forecast Details

Clearly, Broadcom continues to be one of the key companies in the driver's seat when it comes to the AI infrastructure buildout.

These new deals provide further confidence that Broadcom appears well-positioned to convert the three other hyperscalers it’s reportedly in talks with.

Overall, the outlook for this stock continues to look highly promising in the long term.

Shares are now only down around 4% from their all-time highs, meaning that upside could be somewhat limited in the near term. Broadcom’s earnings release in December could be another upside catalyst for the stock.

The MarketBeat consensus price target on AVGO is $372, implying around 5% upside in shares.

However, every price target update tracked by MarketBeat after the OpenAI announcement sits at $400 or higher. This implies at least 13% upside in shares and indicates that shares could hit new highs.

Should You Invest $1,000 in Broadcom Right Now?Before you consider Broadcom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Broadcom wasn't on the list.

While Broadcom currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

More Than Half of Cancers Detected by Galleri Were Early Stage

Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings

PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population  

, /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251. 

PATHFINDER 2 evaluated the safety and performance of the Galleri® multi-cancer early detection (MCED) test when used alongside standard-of-care cancer screenings. The largest interventional study of an MCED test in the United States to date, the prospective PATHFINDER 2 study includes 35,878 enrolled participants across the United States and Canada in a broad, intended-use population of adults aged 50 and older with no clinical suspicion of cancer. Results were presented from a pre-specified analysis of the first 25,578 participants with at least 12 months of follow-up as of Dec. 31, 2024. Of these, 23,161 were analyzable for performance and 25,114 were analyzable for safety.

"Cancer is the second leading cause of death worldwide as most deadly cancers are found too late. Adding Galleri to recommended screening for breast, cervical, colorectal, and lung cancers in PATHFINDER 2 yielded a more than seven-fold increase in the cancer detection rate, and more than half of the Galleri detected new cancers were found in early stages, when cancers are more treatable and potentially even curable. Galleri's ability to accurately predict where in the body the cancer signal comes from also helps to guide a more efficient diagnostic workup," said Josh Ofman, MD, MSHS, President at GRAIL. "These results are extremely compelling as approximately three-quarters of the Galleri-detected cancers do not have recommended screening tests today. Galleri is the only MCED test available that has been validated in an interventional trial in the screening population and could transform how we deliver cancer screening at a population level."

Finding More Cancers, Earlier By Adding the Galleri Test
Data from the performance analyzable cohort of 23,161 participants with 12 months of follow-up found that adding Galleri to recommended screenings for breast, cervical, colorectal, and lung cancers (USPSTF A and B recommendations) led to a more than seven-fold increase in the number of cancers found within a year. Galleri detected approximately three times as many cancers when added to standard-of-care screening for breast, cervical, colorectal, lung, and prostate cancers (USPSTF A, B, and C recommendations). Approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options.

More than half (53.5%) of the new cancers detected by Galleri were stage I or II and more than two-thirds (69.3%) were detected at stages I-III.

"Cancer screening saves lives, but we routinely screen for just four or five cancer types in the United States today and approximately 70% of cancer deaths come from cancers that do not have standard-of-care screening and are typically caught too late," said Nima Nabavizadeh, MD, Associate Professor of Radiation Medicine at Oregon Health & Science University. "Data from PATHFINDER 2 show that Galleri could fundamentally change our approach to cancer screening, helping to detect many types of cancer earlier, when the chance of successful treatment or even cure are the greatest."

High Performance and Low Risk of False Alarms
The Galleri test detected a cancer signal in 216 participants (cancer signal detection rate of 0.93%), and of those, cancer was diagnosed in 133 participants (cancer detection rate of 0.57%). The likelihood of receiving a cancer diagnosis following a positive test result (positive predictive value) was 61.6%, substantially higher than in the previous PATHFINDER study of Galleri.

Since PATHFINDER 2 is a prospective clinical trial where the cancer status of participants is unknown at the outset, episode sensitivity – the ability to detect cancer that could be confirmed within 12 months after the blood draw – is a performance measure of the study. Galleri demonstrated strong performance, with 73.7% episode sensitivity for the 12 cancers responsible for two-thirds of cancer deaths in the U.S. For all cancers, episode sensitivity was 40.4%. Specificity was 99.6%, translating to a false positive rate of only 0.4%.

"Any multi-cancer early detection test used for population screening should aim to detect as many aggressive cancers as possible before symptoms arise and maximize the likelihood that a positive test result is actually cancer. The PATHFINDER 2 results demonstrate that the Galleri test is doing just that, increasing the number of cancers detected more than seven-fold when added to recommended screening for breast, cervical, colorectal, and lung cancers, and with a very low false positive rate," said Ofman. "What's especially promising is that Galleri showed strong sensitivity at detecting many of the cancers responsible for the majority of cancer deaths, which we believe provides clinicians with a clinically valuable and validated screening tool."

High Accuracy of Cancer Signal Origin Enabled Efficient Diagnostic Evaluation
A key benefit of Galleri is its ability to predict where in the body the cancer is coming from. The PATHFINDER 2 study demonstrated that the test correctly identified the Cancer Signal Origin (CSO) 92% of the time, leading to efficient diagnostic workups. Diagnostic resolution took a median of 46 days, and only 0.6% of all participants had an invasive procedure (159/25,114). Invasive procedures were two times more common in participants with cancer than in those without. 

MCED test safety was evaluated in an analyzable cohort of 25,114 participants. No serious, study-related adverse events were reported during the diagnostic workup.

Data from this study will be submitted to the U.S. Food and Drug Administration (FDA) as part of the Galleri premarket approval (PMA) application, along with data from the prevalent screening round of the NHS-Galleri trial. In addition, GRAIL will submit to the FDA a bridging analysis to compare performance of the version of Galleri used in the PATHFINDER 2 study and the NHS-Galleri trial to the updated version that GRAIL plans to submit to the FDA for premarket approval. GRAIL expects to complete the PMA modular submission for Galleri, which is under a Breakthrough Device Designation, in the first half of 2026.

Conference call and webcast with the investment community
GRAIL management will host a conference call and webcast on Oct. 20 at 5 a.m. PT / 8 a.m. ET to discuss results of the PATHFINDER 2 study. A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com. 

Please register for the live event at this link.

To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

About the PATHFINDER 2 Study (NCT05155605)
PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of Galleri in approximately 35,000 individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in the United States. The primary objectives of the study are 1) to evaluate the safety and performance of the Galleri MCED test based on the number and type of diagnostic evaluations performed in participants who receive a cancer signal detected test result, and 2) to evaluate the performance of the Galleri MCED test across various measures, including PPV, negative predictive value (NPV), sensitivity, specificity, and CSO prediction accuracy. Participants who receive a cancer signal detected result undergo additional diagnostic testing based on the predicted CSO to determine if a cancer is present. Secondary objectives include utilization of guideline-recommended cancer screening procedures after use of the MCED test, and participant reported outcomes over several time points, including an assessment of participants' anxiety and satisfaction with the MCED test. 

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, Galleri can detect more than 50 types of cancer before symptoms appear — when they can be easier to treat and are potentially curable2. Galleri is the only available MCED test with demonstrated performance in patients screened for cancer2,*. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market1,2,3,4,**. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up4,5,6. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

For more information, visit galleri.com.

* The Galleri test performance metrics were derived from the outcomes of an interventional clinical study of patients presenting for screening without clinical suspicion of cancer, a study population that reflects the intended use population.

** Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.

Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about GRAIL, Inc. (the "Company"), include the benefits and use of the Galleri test, the potential of the Galleri MCED test, expectations regarding the final results of the PATHFINDER 2 study, upcoming events and presentations, the timeline and results of a bridging analysis to the FDA, the applicability of the PATHFINDER 2 results to the commercial or FDA versions of the Galleri test, and the timeline for completion of the PMA modular submission.

These statements are only predictions based on the Company's current expectations and projections about future events and trends. There are important factors that could cause actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the period ended December 31, 2024 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025. Moreover, the Company operates in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for the Company's management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements.

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Although the Company believes the expectations and projections expressed or implied by the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, the Company undertakes no obligation to update any of these forward-looking statements after the date of this press release to conform prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.

References:

Nabavizadeh N, et al. Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study. Proffered Presentation Presented at: European Society for Medical Oncology (ESMO) Annual Meeting; October 17-21, 2025; Berlin, Germany.
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]
Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2
GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
Hackshaw A, et al. Cancer Cell. 2022;40(2):109-13. 

SOURCE GRAIL, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Oct 17 (Reuters) - Molecular diagnostics firm BillionToOne

(BLLN.O), opens new tab said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.

The Menlo Park, California-based company is looking to raise up to $211.5 million in its IPO by offering 3.8 million shares priced between $49 and $55 apiece.

Sign up here.

The offering comes amidst a rebound in U.S. IPO activity, reversing a slowdown from earlier this year, when trade-policy uncertainty curbed momentum.

Despite the U.S. government shutdown, companies can tap a provision that allows their registrations to become effective automatically, which involves setting their IPO pricing 20 days before the listing instead of finalizing it the night before.

BillionToOne develops molecular diagnostic tests — including a non-invasive prenatal screen and liquid biopsy — for diseases.

The company filed for an IPO earlier this month and reported revenue of $125.5 million in the first half of 2025, compared with $69 million in the year-ago period.

The company will list on the Nasdaq under the "BLLN" ticker symbol.

J.P. Morgan, Wells Fargo and William Blair are among the underwriters for the offering.

Reporting by Aatreyee Dasgupta in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles., opens new tab

The Federal Aviation Administration raised a production limit that the regulator had imposed after a door panel blew off a plane during a flight last year.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 20, 2025 to file lead plaintiff applications in a securities class action lawsuit against Snap Inc. (NYSE: SNAP), if they purchased the Company's securities between April 29, 2025 to August 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for th.

October 17, 2025 6:21 PM EDT | Source: Signature Resources Ltd.
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - Signature Resources Ltd. (TSXV: SGU) (OTCQB: SGGTF) (FSE: 3S30) ("Signature" or the "Company") is pleased to announce that the Board of Directors has granted a combined total of 2,400,000 incentive stock options to the Board, Management and Advisors of the Company. The options have an exercise price of $0.055, in line with the concurrent financing, and expire five years from the grant date. The options vest 25% immediately and 25% annually thereafter until the third anniversary. The options are the only form of compensation provided to non-executive directors of the Company.

All options are subject to the terms and conditions of the Company's Option Plan and applicable regulatory approvals.

About Signature Resources Ltd.

The Company is a Canadian based advanced stage exploration company focused on expanding the 100% Lingman Lake gold deposit, located within the prolific Red Lake district in Northwestern Ontario, Canada. The Lingman Lake gold property (the "Property") consists of 1,274 single-cell and 13 multi-cell staked claims, four freehold fully patented claims and 14 mineral rights patented claims totaling approximately 24,821 hectares. The Property includes what has historically been referred to as the Lingman Lake Gold Mine, an underground substructure consisting of a 126.5-metre shaft, and 3-levels at depths of 46-metres, 84-metres and 122-metres. There has been over 43,222 metres of drilling done on the Property and four 500-pound bulk samples that averaged 19 grams per tonne of gold. The Company's initial mineral resource estimate contain an indicated 95,200 ounces with an average grade of 1.38 g/t Au and and inferred 674,320 ounces at and average grade of 1.14 g/ Au at a cutoff grade of 0.30 g/t. The company is focused on rapidly expanding the known mineralized envelop with its 100% owned diamond drilling rigs. In November 2023, Wataynikaneyap Power energized a new 115kV high tension transmission line within 40 km of the historic Lingman Lake Mine (https://www.wataypower.ca/).

Cautionary Notes

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This news release contains forward-looking statements which are not statements of historical fact. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the Company's objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions and risks associated with infectious diseases and global geopolitical events. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to changes in general economic and financial market conditions, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company's public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270973

Pinterest has successfully transformed into a personalized shopping and inspiration platform, driving strong user and revenue growth. PINS is undervalued relative to its growth, but justified concerns about AI-driven disruption from platforms like ChatGPT and Gemini weigh on its valuation. Despite industry-leading ARPU and revenue gains, PINS still relies on non-GAAP metrics and must improve profitability to reach its full potential.

Fifth Third Bancorp’s third quarter results showed growth in demand deposit accounts, embedded payments and limited exposure to NDFIs.

During the conference call with analysts, CEO Tim Spence took note of the recently-announced Comerica deal and said that “the revenue and expense synergies from Comerica should produce a well-diversified, even more profitable company with even better long-term growth.”

The company’s loan growth stood at 6%, and average demand deposit growth of 3% was outpaced by consumer DDA growth of 6%.

The company added 13 branches in the Southeast and management said that the company is on track to open 27 more branches by the end of 2025. “Consumer households across the Southeast increased by 7% year over year, more than four times the rate of underlying market growth,” Spence said.

“We’ll leverage the same proven de novo playbook, marketing tactics, and differentiated digital offerings to drive retail deposit growth as we add 150 branches to Comerica’s Texas footprint. Together, we’ll have a presence in 17 of the fastest growing large U.S. metro areas … We are excited to add Comerica’s strong verticals to our existing expertise, including in national dealer services, environmental services, and tech and life sciences, among others,” Spence said.

Growth in Embedded Finance
With a nod to commercial payments and specifically the embedded finance platform, fees grew by 3% from the most recent quarter and Newline revenues were up 31% as deposits grew by more than $1 billion, to stand at $3.9 billion at the end of the most recent quarter.

Advertisement: Scroll to Continue

“We expect New Line to sustain its growth as transactional activity ramps from the rollout of Stripe Treasury and many other category-defined payments customers who build on New Line’s APIs,” Spence said. Company materials indicated that within the consumer portfolio, 30 to 89 day delinquencies were 0.47%, flat with the previous quarter and down slightly from a year ago.

CFO Bryan Preston said that Provide, the FinTech lending platform for practice finance, continues to drive growth, with balances up nearly $1 billion over the last year and told analysts that  “pipelines for middle market and corporate banking remain strong heading into year-end … we remain focused on granular insured deposits, growing average consumer and small business deposits by 1% sequentially.”

The net charge-off ratio was 109 basis points for the quarter, which includes $178 million in net charge-offs from Tricolor, said Preston.

“The broad consumer portfolio remains healthy, with non-accrual and over 90 delinquency rates stable to improving across loan categories,” he said.

Management guidance called for loans to be up by 1% in the months ahead, driven in part by consumer lending. The total year adjusted revenue growth is projected to be 5%.

Fifth Third shares were up 1.3% at the close of trading on Friday.

As has been seen with other bank earnings call, the discussion turned to NDFI.

“It’s a portfolio that we have maintained at low levels. We’re at one of the lowest levels of NDFI concentrations of large banks. We’re at about 8% of the total portfolio,” Chief Credit Officer Greg Schroeck said.

33% of the book is tied to real estate and “about 24% of the NDFI balances are to payment processors, insurance companies, brokerage firms, and SBIC firms or funds. Balances in this category are primarily related to large players, well-recognized names, and not at all related to the conversations going on in the markets right now.”

During discussion about tariffs, Spence related that among commercial clients, and with detail on one specific unnamed client, “the quote of the quarter went to the client who referred to his outlook as, quote, ‘nauseously optimistic.’

“The tariff uncertainty absolutely continues to weigh on any clients that are exposed. That said, I would tell you in general, people are more optimistic than they were in the second quarter … the question mark really has been what would be the, who would bear the brunt of the tariffs?” Spence said.

He continued: “I would say now on balance, there’s a sort of a shared pain approach here where the supplier, the intermediary, and the customer are each absorbing about a third of the increased cost … The folks that are having the most robust demand, obviously, are the people who are either attached to the big government infrastructure investments, things like bridges and roads that are moving forward, or the folks that are attached to AI.”

Florida's bold crypto bill and U.S. surplus fuel optimism — Bitcoin price prediction points to a breakout toward $120K.

The embattled cryptocurrency fell to $103K early Friday before clawing its way back to $106K in the afternoon. Jamie Dimon's ‘Cockroach' Remark Deepens Bitcoin Sell-Off An offhanded quip by Jamie Dimon, CEO of JPMorgan Chase (JPM) on Tuesday, may have tanked stocks as fears of a bank credit crunch triggered a multi-day sell-off.

Felix Pinkston
Oct 17, 2025 21:13

Curve (CRV) trades at $0.52 amid broader crypto optimism following the US government's establishment of a Strategic Bitcoin Reserve, though technical indicators suggest caution.

Quick Take
• CRV trading at $0.52 (down 1.4% in 24h)
• US Strategic Bitcoin Reserve announcement provides positive backdrop for crypto sector
• Price testing lower Bollinger Band support zone
• Following broader crypto market weakness despite positive macro developments

Market Events Driving Curve Price Movement
The establishment of a US Strategic Bitcoin Reserve, holding approximately 127,271 BTC valued at $14.2 billion, has created a positive undercurrent in cryptocurrency markets this week. This unprecedented move signals institutional acceptance of digital assets at the highest government level, indirectly benefiting the entire DeFi ecosystem including Curve Finance.

Additionally, corporate Bitcoin holdings reaching $117 billion in Q3 demonstrates continued institutional adoption, with public companies increasingly treating Bitcoin as a treasury reserve asset. This institutional momentum typically flows through to established DeFi protocols like Curve, though CRV price action has remained relatively muted compared to Bitcoin's gains.

Despite these positive developments, CRV has declined 1.45% in the past 24 hours, suggesting that protocol-specific factors or profit-taking may be weighing on the token. The broader crypto market has shown mixed reactions to the news, with some assets consolidating gains while others experience short-term selling pressure.

CRV Technical Analysis: Consolidation Phase
Price Action Context
CRV price currently sits well below all major moving averages, with the token trading at $0.52 compared to the 20-day SMA at $0.66 and 50-day SMA at $0.72. This positioning indicates the token remains in a corrective phase despite the broader positive crypto sentiment. The price action shows CRV has not yet participated meaningfully in the institutional adoption narrative that has lifted Bitcoin and other major cryptocurrencies.

Trading volume on Binance spot markets reached $31 million in 24 hours, representing moderate activity that suggests neither aggressive buying nor panic selling. The volume profile indicates measured trading rather than the explosive moves typically seen during major breakouts or breakdowns.

Key Technical Indicators
The RSI reading of 36.22 places CRV in neutral territory with a slight bearish bias, indicating the token is neither oversold nor overbought. This reading suggests room for further downside movement before reaching oversold conditions that might attract value buyers.

The MACD histogram at -0.0137 confirms bearish momentum remains in place, though the relatively shallow negative reading suggests selling pressure may be moderating. Curve technical analysis shows the Bollinger Bands position at 0.1565, indicating the price is trading near the lower band, which often provides support in trending markets.

Critical Price Levels for Curve Traders
Immediate Levels (24-48 hours)
• Resistance: $0.56 (7-day moving average and recent range high)
• Support: $0.46 (lower Bollinger Band and psychological level)

Breakout/Breakdown Scenarios
A break below $0.46 support could accelerate selling toward the $0.37 yearly low, representing significant downside risk for current holders. Conversely, a reclaim of $0.56 resistance would signal potential stabilization and could target the $0.66 level where the 20-day moving average currently resides.

CRV Correlation Analysis
• Bitcoin: CRV is largely following Bitcoin's broader trend but with greater downside volatility, typical of smaller-cap DeFi tokens during uncertain periods
• Traditional markets: The S&P 500's stability has provided a neutral backdrop, neither helping nor hindering crypto markets significantly
• Sector peers: Other DeFi tokens have shown similar consolidation patterns, suggesting sector-wide profit-taking rather than Curve-specific issues

Trading Outlook: Curve Near-Term Prospects
Bullish Case
Sustained institutional Bitcoin adoption could eventually flow into established DeFi protocols like Curve, particularly if the Strategic Bitcoin Reserve leads to broader crypto regulation clarity. A successful defense of $0.46 support combined with increased DeFi activity could spark a recovery toward $0.66-$0.72 resistance zone.

Bearish Case
Failure to hold current support levels amid potential profit-taking in the broader crypto market could see CRV price decline toward yearly lows. Weak DeFi sector performance or broader market correction could pressure the token further despite positive macro developments.

Risk Management
Conservative traders should consider stop-losses below $0.45 to limit downside exposure, while position sizing should account for the elevated volatility indicated by the 14-day ATR of $0.09. The current technical setup favors patience over aggressive positioning until clearer directional signals emerge.

Image source: Shutterstock

crv price analysis
crv price prediction

TL;DR

Ripple plans to raise $1 billion in XRP through a SPAC to create a Digital Asset Treasury, a move that has split the market between enthusiasm and skepticism.
The initiative follows Ripple’s $1 billion acquisition of GTreasury and reflects the company’s interest in treasury models used by MicroStrategy and Metaplanet.
Analysts warn that an XRP-based treasury could expose Ripple to liquidity and volatility risks, while others see it as a bet to strengthen the token’s utility.

Ripple announced an ambitious plan to raise $1 billion in XRP through a SPAC and allocate the funds to a Digital Asset Treasury (DAT), a move that has already divided market sentiment between optimists and skeptics.

If completed, it would mark one of the largest XRP-focused operations to date and signal the company’s intent to reinforce its balance sheet using its own token. However, it also opens a debate on the distinction between real value creation and financial engineering.

The initiative came shortly after Ripple confirmed the $1 billion acquisition of GTreasury, a move aligned with its interest in corporate treasury management tools.

The reference to models like MicroStrategy and Metaplanet is clear: turning a strategic crypto position into a treasury asset that, in theory, could generate value for the company. Yet, the comparison also has fine print—digital treasuries are fragile when markets panic, and sudden downturns can trigger forced sales or erode the expected advantage.

Ripple’s Proposal Splits the Community
The market turmoil on October 10, marked by massive liquidations and risk aversion, exposed the sensitivity of DATs and their dependence on favorable liquidity conditions. In that context, some analysts and community members questioned whether buying large amounts of one’s own token is a growth strategy or simply an attempt to prop up prices. The criticism centers on manipulation concerns and the difficulty of turning buybacks into genuine adoption.

Supporters, however, argue that a strong XRP treasury could enhance the token’s utility and foster new liquidity and product initiatives within Ripple’s ecosystem. They see the plan as an institutional-level bet that demonstrates conviction and long-term commitment to the token’s development.

Ripple’s proposal presents a crossroads for the community: on one side, the opportunity to build a strategic position in XRP; on the other, the challenge of proving that such accumulation will lead to real adoption and utility rather than a temporary price boost. As the details are finalized, the market awaits the outcome and potential impact of this new initiative

Darius Baruo
Oct 17, 2025 21:19

Injective price trades at $8.41 near technical support after reaching record transaction milestone, with Bitcoin's $110K breakthrough providing market-wide momentum for recovery.

Quick Take
• INJ trading at $8.41 (down 2.0% in 24h)
• Record transaction milestone achieved signals growing network adoption
• Price testing critical lower Bollinger Band support at $7.55
• Bitcoin's surge past $110,000 lifting broader crypto sentiment

Market Events Driving Injective Price Movement
Injective Protocol's announcement of surpassing a significant transaction milestone on October 15 has emerged as the primary bullish catalyst for INJ price action this week. The achievement indicates accelerating network activity and adoption, contributing to a 3% price increase following the announcement. This fundamental development demonstrates the protocol's growing utility in the decentralized finance ecosystem.

Bitcoin's breakthrough past $110,000 on October 14 created a positive ripple effect across the cryptocurrency market, with INJ benefiting from the broader altcoin rally that delivered a 5% price boost. The milestone reinforced institutional confidence in digital assets and provided crucial momentum for risk-on positioning in crypto markets.

The Federal Reserve's decision to maintain interest rates on October 13, citing ongoing inflation concerns, had a neutral impact on INJ price. While the decision avoided additional pressure on risk assets, it also limited the potential for aggressive capital rotation into cryptocurrencies.

INJ Technical Analysis: Testing Critical Support Zone
Price Action Context
INJ price currently trades significantly below all major moving averages, with the token positioned at $8.41 compared to the 20-day SMA at $11.14 and 50-day SMA at $12.40. The 24-hour trading range of $7.77 to $8.75 highlights the ongoing consolidation near technical support levels. Injective technical analysis reveals the price is testing the lower Bollinger Band at $7.55, representing a critical juncture for near-term direction.

Trading volume on Binance spot reached $10.87 million in the past 24 hours, indicating moderate institutional interest despite the price decline. The volume profile suggests accumulation near current levels rather than panic selling.

Key Technical Indicators
The RSI reading of 31.45 places INJ in neutral territory with room for recovery without reaching oversold conditions. The MACD histogram at -0.2825 confirms bearish momentum, though the narrowing gap between MACD and signal lines suggests potential stabilization.

Bollinger Bands positioning shows INJ at 0.1197 %B, indicating the price sits very close to the lower band support. This technical setup often precedes either a bounce or a significant breakdown, making the next 48 hours critical for direction.

Critical Price Levels for Injective Traders
Immediate Levels (24-48 hours)
• Resistance: $9.08 (7-day moving average confluence)
• Support: $7.55 (lower Bollinger Band and psychological level)

Breakout/Breakdown Scenarios
A break below $7.55 support could trigger selling toward the strong support zone at $2.74, representing significant downside risk. Conversely, reclaiming the $9.08 level would signal potential recovery toward the $11.14 resistance at the 20-day moving average.

INJ Correlation Analysis
Injective demonstrates strong correlation with Bitcoin's price movements, as evidenced by the 5% rally following BTC's $110,000 breakthrough. This correlation suggests INJ price will likely follow Bitcoin's lead in the near term, making BTC technical levels crucial for INJ traders.

Traditional market correlations remain muted, with the Federal Reserve's rate decision having minimal direct impact on INJ price action. The focus remains on crypto-specific catalysts and Bitcoin's momentum.

Trading Outlook: Injective Near-Term Prospects
Bullish Case
The transaction milestone achievement provides fundamental support for higher valuations, while the oversold technical condition near lower Bollinger Band support creates potential for a relief rally. A sustained Bitcoin rally above $110,000 could drive INJ toward the $11.14 resistance level.

Bearish Case
Failure to hold $7.55 support combined with Bitcoin weakness could trigger accelerated selling toward the $2.74 major support zone. The bearish MACD configuration suggests downside momentum remains intact.

Risk Management
Conservative traders should consider stop-losses below $7.50 to limit downside exposure. Given the Average True Range of $1.28, position sizing should account for potential 15-20% daily volatility swings.

Image source: Shutterstock

inj price analysis
inj price prediction

Since making its debut ahead of President Trump's inauguration in January, it has been a steady slide for the TRUMP token.

Iris Coleman
Oct 17, 2025 21:30

Algorand trades at $0.18 after Bitcoin's 5% weekly decline pressures altcoins, with ALGO price testing critical technical support levels amid mixed ecosystem signals.

Quick Take
• ALGO trading at $0.18 (down 3.1% in 24h)
• Bitcoin's weekly decline creating selling pressure across altcoins
• Price testing lower Bollinger Band support at current levels
• Technical indicators showing oversold conditions developing

Market Events Driving Algorand Price Movement
Bitcoin's approximately 5% decline over the past week has created a cascading effect across the broader cryptocurrency market, with ALGO price following the broader risk-off sentiment. The leading cryptocurrency closed at $108,186 on October 16, marking a significant weekly pullback that has weighed heavily on altcoin performance.

Despite this macro headwind, Algorand's ecosystem fundamentals showed notable strength with monthly active users surging 34% to 1.34 million in Q3 2025. This growth was driven by increased dApp adoption and initiatives like Coinbase Quests, though governance changes including the removal of staking features have sparked some community skepticism.

The technical momentum indicators from earlier this week suggested potential targets in the $0.26-$0.29 resistance zone, representing 13-26% upside potential. However, Bitcoin's renewed weakness has temporarily overshadowed these positive technical setups, with ALGO price now testing critical support levels.

ALGO Technical Analysis: Testing Lower Band Support
Price Action Context
ALGO price currently sits at the lower Bollinger Band at $0.18, representing a critical technical juncture. The cryptocurrency is trading below all major moving averages, with the 7-day SMA at $0.19 providing immediate overhead resistance. The 20-day, 50-day, and 200-day SMAs all converging around $0.21-$0.22 suggests this level will act as significant resistance on any recovery attempt.

Trading volume on Binance spot market reached $9.67 million in the past 24 hours, indicating moderate institutional interest despite the price decline. The current positioning below key moving averages reflects the broader crypto market's correlation with Bitcoin's recent weakness.

Key Technical Indicators
The RSI has dropped to 37.06, approaching oversold territory and suggesting potential for a technical bounce if Bitcoin stabilizes. The MACD remains in bearish territory at -0.0097, though the histogram at -0.0022 shows momentum may be slowing.

Algorand technical analysis reveals the Stochastic oscillator at 60.46/%K and 66.36/%D, indicating the market isn't deeply oversold yet, which could allow for further downside if Bitcoin continues declining.

Critical Price Levels for Algorand Traders
Immediate Levels (24-48 hours)
• Resistance: $0.19 (7-day moving average and previous support turned resistance)
• Support: $0.17 (24-hour low and psychological round number)

Breakout/Breakdown Scenarios
A break below $0.17 would target the strong support zone at $0.10, representing the yearly low area. Conversely, a reclaim of $0.19 could spark a relief rally toward $0.21 where multiple moving averages converge.

ALGO Correlation Analysis
Bitcoin correlation remains strong, with ALGO price movements closely tracking the broader crypto market leader's direction. The 5% Bitcoin decline this week directly contributed to ALGO's 3.1% daily loss and broader weekly weakness.

Traditional markets haven't shown significant correlation recently, with crypto-specific factors and Bitcoin's performance being the primary drivers. Among DeFi and smart contract platforms, Algorand is performing in line with sector peers during this risk-off period.

Trading Outlook: Algorand Near-Term Prospects
Bullish Case
A Bitcoin stabilization above $108,000 could allow ALGO price to bounce from current lower Bollinger Band support. The RSI approaching oversold levels creates conditions for a technical rebound toward $0.21-$0.22 resistance cluster.

Bearish Case
Continued Bitcoin weakness below $108,000 would likely pressure ALGO toward the $0.17 support level and potentially the strong support zone at $0.10. The MACD remaining in negative territory suggests downside momentum could persist.

Risk Management
Traders should consider stop-losses below $0.17 for long positions, with the daily ATR of $0.02 providing guidance for position sizing. The current volatility environment suggests keeping position sizes modest until Bitcoin establishes a clearer directional bias.

Image source: Shutterstock

algo price analysis
algo price prediction

The ongoing competition between Binance and Coinbase has intensified after Binance founder Changpeng Zhao (CZ) publicly called on Coinbase to list more BNB Chain projects. The statement comes shortly after Coinbase added BNB to its official listing roadmap, signaling tentative engagement with the Binance ecosystem.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

ETF issuer Volatility Shares recently filed with the US SEC to launch highly leveraged XRP ETFs, alongside other cryptocurrencies and stocks. Particularly, Volatility Shares has decided to file for a 5× leveraged XRP ETF, a move that caught many traders and analysts off guard. 

Discussions have intensified among investors following the filing, as it stands out as one of the boldest attempts yet in the crypto ETF world, especially since the SEC has yet to even approve any 3× leveraged crypto products.

Volatility Shares’ Expansive ETF Filing
According to filings, Volatility Shares is planning to launch both 3x and 5x leveraged ETFs tracking the price of XRP alongside other major cryptocurrencies such as Solana, Bitcoin, and Ethereum. The ETF proposed by Volatility Shares will use futures, swaps and options to achieve a magnified daily performance exposure.

The move signals that the issuer is prepared to push the limits of what the US Securities and Exchange Commission (SEC) might tolerate, creating a major twist in the increasing popularity of investment funds linked to digital assets. If approved, the earliest activation date for these leveraged ETFs is December 29, 2025.

Market analysts were taken aback, with the filing seeing mixed reactions on social media platforms. ETF expert Henry Jim announced the scope of Volatility Shares’ filing on the social-media platform X. In his post, he exclaimed, “Sonic BOOOM! — 27 leveraged 3× and 5× single-stock ETFs filed by Volatility Shares!

His list of the Volatility Shares’ filing included tech heavyweights such as AMD, Amazon, Google, Nvidia, Palantir, and Tesla, alongside crypto-focused funds for Bitcoin, Ethereum, Solana, and XRP, and crypto-related stocks such as crypto exchange Coinbase and Bitcoin treasury firm Strategy. The extensive slate indicates that Volatility Shares is attempting to corner both the equity and crypto leverage markets.

Bloomberg ETF analyst Eric Balchunas also expressed astonishment regarding the filings. Balchunas added that the firm could be making an option on a long-term government shutdown, since if there’s no SEC action in 75 days, they can launch.

Risks Of Highly Leveraged ETFs
Volatility Shares’ proposal for a 5× leveraged ETF comes in the aftermath of the most severe crypto market liquidations, where over $19 billion was wiped out across crypto exchanges in a single weekend. Data from derivatives platforms showed that the majority of those liquidations came from highly leveraged positions. 

Therefore, these proposed ETFs are a double-edged sword in terms of contributions to the crypto market. For one, it could provide an avenue for more institutional funds into XRP and other cryptocurrencies. If successful, these ETFs could also set a precedent for future high-risk crypto products in the US market. 

On the other hand, the risk is also magnified. If XRP falls by 2% in a day, the 5× leveraged fund will lose 10%, and that’s just in one day.

XRP trading at $2.2 on the 1D chart | Source: XRPUSDT on Tradingview.com
Featured image from Adobe Stock, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Dogecoin's next inflection could arrive as soon as October 22–23, according to crypto analyst VisionPulsed, who argues that the memecoin's multi-month rising channel will either confirm with a higher low in the $0.16–$0.18 region or give way to another full “round trip” into year-end.

XRP has continued to spark fears among investors as whales are increasingly dumping their tokens amid ongoing market uncertainty. 

On Friday, October 17, on-chain tracking platform Whale Alert shared data showing over 106 million XRP being transferred in a move that appears to be an attempt to sell.

The tracker spotted two large, consecutive transactions — 53,399,340 XRP and 53,356,907 XRP — being moved between unknown wallets and Coinbase.

HOT Stories

While both transfers are collectively worth over $242 million, commentators have suggested that whales may be strategically dumping their holdings to hedge against further losses.

Although the exact nature of the transactions was not disclosed, they signal mounting sell pressure, which could weigh heavily on price performance and trigger deeper corrections.

While some commentators have speculated that one of the transactions might be an OTC (over-the-counter) transfer occurring outside of a crypto exchange, many others have expressed skepticism, believing that both transfers were influenced by the prevailing negative market sentiment.

 XRP to retest $1?With the XRP market structure appearing increasingly weak and on the verge of a total collapse, there are few, if any, support levels left between current prices and the psychological threshold of $1.00.

This suggests that XRP could retest the $1 level in the near term if market momentum does not turn bullish soon. Beyond the increasing selling activity observed in the market, whales have continued to liquidate large positions, putting overall liquidity under significant pressure.

However, despite the consistent price declines, analysts remain optimistic about XRP’s long-term prospects. Analysts attribute this optimism to Ripple’s recent developments, highlighting reasons why investors should remain bullish on XRP despite the distressed market conditions.

As Ripple continues to aggressively expand its global presence — through major developments such as the launch of its RLUSD stablecoin in Africa and its custody partnership with Absa Bank — the demand for XRP is expected to rise to new heights.

These initiatives, which strengthen XRP’s utility in cross-border payments, are anticipated to support a longer-term recovery for the asset despite the ongoing market bloodbath.